Patients with high BCL2 and/or high MYC expression according to treatment arm and age
| n (%) . | Ibrutinib + R-CHOP (n = 386) . | Placebo + R-CHOP (n = 380) . |
|---|---|---|
| All ages | ||
| BCL2-high | 196 (50.8) | 187 (49.2) |
| MYC-high | 199 (51.6) | 183 (48.2) |
| MYC-high + BCL2-high | 123 (31.9) | 111 (29.2) |
| <60 y | ||
| n | 149 | 168 |
| MYC-high + BCL2-high | 47 (31.5) | 50 (29.8) |
| ≥60 y | ||
| n | 237 | 212 |
| MYC-high + BCL2-high | 76 (32.1) | 61 (28.8) |
| n (%) . | Ibrutinib + R-CHOP (n = 386) . | Placebo + R-CHOP (n = 380) . |
|---|---|---|
| All ages | ||
| BCL2-high | 196 (50.8) | 187 (49.2) |
| MYC-high | 199 (51.6) | 183 (48.2) |
| MYC-high + BCL2-high | 123 (31.9) | 111 (29.2) |
| <60 y | ||
| n | 149 | 168 |
| MYC-high + BCL2-high | 47 (31.5) | 50 (29.8) |
| ≥60 y | ||
| n | 237 | 212 |
| MYC-high + BCL2-high | 76 (32.1) | 61 (28.8) |